Nuveen Asset Management LLC raised its stake in Chemours Company (The) (NYSE:CC) by 145.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 67,730 shares of the specialty chemicals company’s stock after buying an additional 40,156 shares during the period. Nuveen Asset Management LLC’s holdings in Chemours Company (The) were worth $2,608,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of CC. Ropes Wealth Advisors LLC raised its position in Chemours Company (The) by 82.4% in the first quarter. Ropes Wealth Advisors LLC now owns 3,099 shares of the specialty chemicals company’s stock worth $119,000 after buying an additional 1,400 shares during the period. Schroder Investment Management Group bought a new stake in shares of Chemours Company (The) during the first quarter valued at about $156,000. Cypress Capital Management LLC WY raised its stake in shares of Chemours Company (The) by 1.9% in the first quarter. Cypress Capital Management LLC WY now owns 4,196 shares of the specialty chemicals company’s stock valued at $162,000 after buying an additional 80 shares during the last quarter. Clean Yield Group bought a new stake in shares of Chemours Company (The) during the first quarter valued at about $167,000. Finally, United Capital Financial Advisers LLC bought a new stake in shares of Chemours Company (The) during the first quarter valued at about $203,000. Hedge funds and other institutional investors own 75.21% of the company’s stock.

Shares of Chemours Company (NYSE:CC) traded down 5.16% during mid-day trading on Tuesday, hitting $47.20. 3,850,249 shares of the stock were exchanged. Chemours Company has a 12 month low of $9.12 and a 12 month high of $50.04. The firm has a market cap of $8.73 billion, a P/E ratio of 30.87 and a beta of 3.63. The stock’s 50 day moving average is $42.16 and its 200 day moving average is $37.26.

Chemours Company (The) (NYSE:CC) last issued its quarterly earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.02. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the prior year, the business earned $0.27 EPS. Chemours Company (The)’s revenue was up 14.8% on a year-over-year basis. Analysts expect that Chemours Company will post $3.51 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Thursday, August 17th will be issued a dividend of $0.03 per share. The ex-dividend date is Tuesday, August 15th. This represents a $0.12 annualized dividend and a yield of 0.25%. Chemours Company (The)’s dividend payout ratio (DPR) is 8.11%.

WARNING: “Chemours Company (The) (CC) Position Raised by Nuveen Asset Management LLC” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/08/nuveen-asset-management-llc-increases-position-in-chemours-company-the-cc-updated-updated-updated.html.

Several equities research analysts have issued reports on CC shares. Citigroup Inc. reiterated a “neutral” rating and set a $40.00 target price (up from $34.00) on shares of Chemours Company (The) in a research report on Friday, April 14th. ValuEngine upgraded shares of Chemours Company (The) from a “hold” rating to a “buy” rating in a report on Friday, June 2nd. J P Morgan Chase & Co upgraded shares of Chemours Company (The) from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $39.00 to $50.00 in a report on Friday, May 12th. Zacks Investment Research raised shares of Chemours Company (The) from a “hold” rating to a “strong-buy” rating and set a $51.00 target price on the stock in a research note on Friday, July 14th. Finally, BidaskClub downgraded shares of Chemours Company (The) from a “buy” rating to a “hold” rating in a research note on Saturday, June 17th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Chemours Company (The) presently has an average rating of “Buy” and a consensus target price of $46.25.

In other Chemours Company (The) news, VP Erich Parker sold 4,908 shares of the company’s stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $45.53, for a total transaction of $223,461.24. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Paul Kirsch sold 19,036 shares of the company’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $41.42, for a total value of $788,471.12. The disclosure for this sale can be found here. 1.14% of the stock is owned by corporate insiders.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Stock Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related stocks with our FREE daily email newsletter.